8-K: Corvus Pharmaceuticals Announces Positive Interim Data and First Quarter 2025 Financial Results

Corvus Pharmaceuticals reports encouraging interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis and provides a business update alongside its first quarter 2025 financial results.

Summary

• Corvus Pharmaceuticals announced interim data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis, showing a favorable safety and efficacy profile.
• Cohort 3 (200 mg twice daily) demonstrated earlier and deeper responses compared to cohorts 1 and 2 (100 mg twice daily and 200 mg once daily).
• All three cohorts showed significant responses in the soquelitinib treatment groups compared to placebo for clinically significant endpoints of EASI 75 and IGA 0 or 1.
• The company amended the clinical trial protocol to replace cohort 4 with 24 patients randomized 1:1 between active and placebo, extending treatment to 8 weeks at the same dose as cohort 3.
• Corvus continues to enroll patients in a Phase 3 clinical trial of soquelitinib in patients with relapsed PTCL.
• The company is collaborating with the Kidney Cancer Research Consortium (KCRC) in a Phase 1b/2 clinical trial evaluating ciforadenant as a potential first-line therapy for metastatic renal cell cancer (RCC).
• As of March 31, 2025, Corvus had cash, cash equivalents, and marketable securities of $44.2 million.
• In May 2025, warrant exercises provided cash proceeds of approximately $31.3 million.
• Corvus expects its cash to fund operations into the fourth quarter of 2026.
• Net income for the three months ended March 31, 2025, was $15.2 million, including a gain of $25.1 million associated with the change in fair value of the company's warrant liability.

Sentiment

Score: 7

Explanation: The document presents positive clinical trial data and financial updates, but also acknowledges risks and uncertainties inherent in drug development. The sentiment is cautiously optimistic.

Positives

• Soquelitinib demonstrated a favorable safety and efficacy profile in the Phase 1 trial for atopic dermatitis.
• Cohort 3 showed earlier and deeper responses, suggesting an optimal dosing strategy.
• Significant responses were observed in all three cohorts compared to placebo for clinically meaningful endpoints.
• The company secured $31.3 million in cash proceeds from warrant exercises.
• Current cash is expected to fund operations into the fourth quarter of 2026.
• Net income for the first quarter of 2025 was $15.2 million.

Negatives

• The company had cash, cash equivalents, and marketable securities of $44.2 million as of March 31, 2025, compared to $52.0 million as of December 31, 2024, indicating a decrease in cash reserves.
• Research and development expenses increased by approximately $3.4 million compared to the same period in 2024.

Risks

• The company's ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials is a risk.
• The accuracy of the company's estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials is a risk.
• The results of preclinical studies and interim data from clinical trials may not be predictive of future results.
• The company's ability to enroll sufficient numbers of patients in its clinical trials is a risk.
• The unpredictability of the regulatory process poses a risk.
• Regulatory developments in the United States and foreign countries could impact the company.
• The costs of clinical trials may exceed expectations.
• The company's ability to raise additional capital is a risk.

Future Outlook

Corvus expects its cash to fund operations into the fourth quarter of 2026 and plans to initiate a Phase 2 clinical trial for soquelitinib in atopic dermatitis before year-end.

Management Comments

• Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus, stated that the new soquelitinib data supports its potential to be a meaningful new treatment for atopic dermatitis.
• Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus, stated that they remain on track with key potential value-driving initiatives for soquelitinib in atopic dermatitis.
• Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus, stated that they are excited about other soquelitinib clinical programs.
• Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus, stated that they believe the results are particularly exciting given the relatively short treatment duration of 28 days and durable post-treatment results.

Industry Context

The announcement highlights Corvus's progress in the competitive fields of atopic dermatitis and T cell lymphoma, where new and effective treatments are in high demand. The company's ITK inhibitor approach represents a novel mechanism of action that could differentiate it from existing therapies.

Comparison to Industry Standards

• The EASI 75 and IGA 0 or 1 endpoints achieved by soquelitinib are clinically meaningful and approvable endpoints, similar to those used in clinical trials for other FDA-approved treatments for atopic dermatitis, such as Dupixent (dupilumab) from Sanofi and Regeneron.
• The company's approach to ITK inhibition is novel and could provide a new mechanism of action compared to existing treatments like topical corticosteroids, calcineurin inhibitors, and biologics.
• The Phase 3 trial in PTCL is significant as there are no FDA fully approved agents for the treatment of relapsed PTCL, creating a potential market opportunity for soquelitinib.

Stakeholder Impact

• Positive clinical trial results could benefit patients with atopic dermatitis and T cell lymphoma by providing new treatment options.
• The company's financial stability, supported by warrant exercises, could reassure investors.
• Advancement of clinical programs could create opportunities for employees and collaborators.

Next Steps

• The company plans to initiate a Phase 2 clinical trial for soquelitinib in atopic dermatitis before year-end.
• Corvus will continue to enroll patients in the Phase 3 clinical trial of soquelitinib in patients with relapsed PTCL.
• The company will continue to follow patients in the Phase 1b/2 clinical trial evaluating ciforadenant in combination with ipilimumab and nivolumab for metastatic renal cell cancer (RCC).
• Angel Pharmaceuticals will continue to evaluate data from its Phase 1/1b clinical trial of mupadolimab in patients with relapsed non-small cell lung cancer (NSCLC).

Key Dates

Keywords

soquelitinib, atopic dermatitis, clinical trial, ITK inhibitor, peripheral T cell lymphoma, PTCL, EASI, IGA, financial results, Corvus Pharmaceuticals